Lower dosages of phentermine-fenfluramine given in the afternoon: Five cases with significant weight loss

International Journal of Eating Disorders

Volumn 25, Issue 4, 1999, Pages 469-474

  Katz, Debra A ^a,d   Maloney, Michael J ^b   Sutkamp, Jerry C ^c   McConville, Brian J ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Sutkamp Clinic   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Fenfluramine; Phentermine; Pulmonary hypertension

Indexed keywords

DIURETIC AGENT; FENFLURAMINE; LISINOPRIL; PHENTERMINE;

ADULT; ARTICLE; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MITRAL VALVE REGURGITATION; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0032944375     PISSN: 02763478     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-108X(199905)25:4<469::AID-EAT13>3.0.CO;2-H     Document Type: Article

References (24)

1. Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simmoneau, G., & Begaud, B. (1996). Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New England Journal of Medicine, 335, 609-616.
2. Atkinson, R.L., Blank, R.C., Schumacher, D., Levine, J., & Ritch, D.L. (1993). Combination drug treatment of obesity in a practice setting. Obesity Research, 1 (Suppl. 2), 825.
3. Basderant, A., Craplet, C., & Guy-Grand, B. (1993). Snacking patterns in obese French women. Appetite, 21, 17-23.
4. Blackburn, G.L., & Kanders, B.S. (1987). Medical evaluation and treatment of the obese patient with cardiovascular disease. American Journal of Cardiology, 60, 55G-58G.
5. Blackburn, G.L., & Read, J.L. (1984). Benefits of reducing - revisited. Postgraduate Medical Journal, 60 (Suppl. 3), 13-18.
6. Blundell, J.E., Latham, C.J., & Lesham, M.B. (1976). Differences between the anorexic actions of amphetamine and fenfluramine: Possible effects on hunger and satiety. Journal of Pharmacy and Pharmacology, 28, 471-477.
7. Bray, G.A. (1995). Evaluation of drugs for treating obesity. Obesity Research, 3 (Suppl. 4), 4255-4345.
8. Bruce, B., & Agras, W.S. (1992). Binge eating in females: A population-based investigation. International Journal of Eating Disorders, 12, 365-373.
9. Connolly, H.M., Crary, J.L., & McGoon M.D. (1997). Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine, 337, 581-588.
10. Goldstein, D.J. (1991). Beneficial effects of modest weight loss. International Journal of Obesity, 16, 397-415.
11. Kuldau, J.M., & Rand, C.S.W. (1986). The night eating syndrome and bulimia in the morbidly obese. International Journal of Eating Disorders, 5, 143-148.
12. Marcus, M.D., Smith, D., Santelli, R., & Kaye, W. (1992). Characterization of eating disordered behavior in obese binge eaters. International Journal of Eating Disorders, 12, 249-255.
13. McGinnis, J.M., & Foege, W.H. (1993). Actual causes of death in the United States. Journal of the American Medical Association, 2207-2212.
14. The National Task Force on the Prevention and Treatment of Obesity. (1996). Long-term pharmacotherapy in the management of obesity. Journal of the American Medical Association, 276, 1907-1915.
15. Rogers, P.J., & Blundell, J.E. (1979). Effects of anorexic drugs on food intake and the microstructure of eating in human subjects. Psychopharmacology, 66, 159-165.
16. Stadel, B. (1995). Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee Meeting Condensed Transcript and Concordance (pp. 261-268). Washington, DC: SAG Corp.
17. Stunkard, A., Berkowitz, R., Wadden, T., et al. (1996). Binge eating disorder and the night-eating syndrome. International Journal of Obesity, 20, 1-6.
18. Stunkard, A.J., Grace, W.J., & Wolff, H.G. (1995). The night eating syndrome. American Journal of Medicine, 19, 78-86.
19. Weintraub, M. (1992). Long-term weight control study conclusions. Clinical Pharmacology and Therapeutics, 51, 642-646.
20. Weintraub, M., Sundaresan, P.R., Madan, M., Schuster, B., Balder, A., & Lasagna, L. (1992). Long term weight control study I (weeks 0 to 34). Clinical Pharmacology and Therapeutics, 51, 586-594.
21. Weintraub, M., Sundaresan, P.R., Schuster, B., Ginsberg, G, Madan, M., Balder, A., Stein, E.L., Byrne, L. (1992). Long term weight control study II (weeks 34 to 104). Clinical Pharmacology and Therapeutics, 51, 595-601.
22. Williamson, D.F., Pamuk, E., Thun, M., Flanders, D., Byers, T., & Heath, C. (1995). Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. American Journal of Epidemiology, 141, 1128-1141.
23. Wing, R.R., & Greeno, C.G. (1994). Behavioral and psychosocial aspects of obesity and its treatment. Baillieres Clinical Endocrinology and Metabolism, 8, 689-703.
24. Yanovski, S.Z. (1993). Binge eating disorder: Current knowledge and future directions. Obesity Research, 1, 306-324.